JP2023535443A5 - - Google Patents

Info

Publication number
JP2023535443A5
JP2023535443A5 JP2023504620A JP2023504620A JP2023535443A5 JP 2023535443 A5 JP2023535443 A5 JP 2023535443A5 JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023535443 A5 JP2023535443 A5 JP 2023535443A5
Authority
JP
Japan
Prior art keywords
complex
antibody
composition
molecular payload
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023504620A
Other languages
English (en)
Japanese (ja)
Other versions
JP7803925B2 (ja
JP2023535443A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040984 external-priority patent/WO2022020105A1/en
Publication of JP2023535443A publication Critical patent/JP2023535443A/ja
Publication of JP2023535443A5 publication Critical patent/JP2023535443A5/ja
Priority to JP2026002189A priority Critical patent/JP2026077638A/ja
Application granted granted Critical
Publication of JP7803925B2 publication Critical patent/JP7803925B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023504620A 2020-07-23 2021-07-09 抗トランスフェリン受容体(TfR)抗体およびその使用 Active JP7803925B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026002189A JP2026077638A (ja) 2020-07-23 2026-01-08 抗トランスフェリン受容体(TfR)抗体およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063055721P 2020-07-23 2020-07-23
US63/055,721 2020-07-23
US202063069071P 2020-08-23 2020-08-23
US63/069,071 2020-08-23
US202163143825P 2021-01-30 2021-01-30
US63/143,825 2021-01-30
PCT/US2021/040984 WO2022020105A1 (en) 2020-07-23 2021-07-09 Anti-transferrin receptor (tfr) antibody and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026002189A Division JP2026077638A (ja) 2020-07-23 2026-01-08 抗トランスフェリン受容体(TfR)抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2023535443A JP2023535443A (ja) 2023-08-17
JP2023535443A5 true JP2023535443A5 (cg-RX-API-DMAC7.html) 2024-07-17
JP7803925B2 JP7803925B2 (ja) 2026-01-21

Family

ID=79729848

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023504620A Active JP7803925B2 (ja) 2020-07-23 2021-07-09 抗トランスフェリン受容体(TfR)抗体およびその使用
JP2026002189A Pending JP2026077638A (ja) 2020-07-23 2026-01-08 抗トランスフェリン受容体(TfR)抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026002189A Pending JP2026077638A (ja) 2020-07-23 2026-01-08 抗トランスフェリン受容体(TfR)抗体およびその使用

Country Status (11)

Country Link
US (1) US20230256112A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185315A4 (cg-RX-API-DMAC7.html)
JP (2) JP7803925B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230041760A (cg-RX-API-DMAC7.html)
CN (1) CN116348138A (cg-RX-API-DMAC7.html)
AU (1) AU2021312708A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001005A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186727A1 (cg-RX-API-DMAC7.html)
IL (1) IL299667A (cg-RX-API-DMAC7.html)
MX (1) MX2023000962A (cg-RX-API-DMAC7.html)
WO (1) WO2022020105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
MX2023000984A (es) * 2020-07-23 2023-05-03 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
CA3230796A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法
US20260015409A1 (en) * 2022-09-20 2026-01-15 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
IL327952A (en) * 2023-10-26 2026-06-01 Biogen Ma Inc Anti-transferrin receptor antibodies and uses thereof
WO2025140522A1 (en) * 2023-12-29 2025-07-03 Nona Biosciences (Suzhou) Co., Ltd. Anti-tfr1 antibodies, preparation methods and uses thereof
CN119192378B (zh) * 2024-10-16 2025-10-17 中国人民解放军军事科学院军事医学研究院 一种pH敏感型人源抗转铁蛋白受体1抗体
CN119161483B (zh) * 2024-10-16 2026-02-06 中国人民解放军军事科学院军事医学研究院 人源抗转铁蛋白受体1抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734799B2 (en) * 2010-04-13 2014-05-27 The Regents Of The University Of California Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
SG11201509566RA (en) * 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
FR3049951A1 (fr) * 2016-04-12 2017-10-13 Univ Rabelais Francois Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
UY38247A (es) * 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3829594A4 (en) 2018-08-02 2022-05-11 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
CN112930193A (zh) * 2018-08-02 2021-06-08 达因疗法公司 肌肉靶向复合物及其在治疗肌肉萎缩中的用途
IL312067B2 (en) * 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof

Similar Documents

Publication Publication Date Title
US12121527B2 (en) Anthracycline-based antibody drug conjugates having high in vivo tolerability
JP2023511774A5 (cg-RX-API-DMAC7.html)
US12377144B2 (en) Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
CN106029083B (zh) 亲水性抗体-药物偶联物
US20230073692A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2022513420A5 (cg-RX-API-DMAC7.html)
JP2021516960A5 (cg-RX-API-DMAC7.html)
JP2012529891A5 (cg-RX-API-DMAC7.html)
JP2018532715A5 (cg-RX-API-DMAC7.html)
JP2008515889A5 (cg-RX-API-DMAC7.html)
JP2026505129A (ja) 抗cdh17抗体及びその使用
WO2022001710A1 (zh) 用于抗体与药物偶联体(adc)制备的中间体及其制备方法和应用
JP2025539702A (ja) 肥満症を治療する方法
US20110142756A1 (en) Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer
CN108452319A (zh) 靶向cd20的抗体偶联药物制剂
TW201905000A (zh) 含有抗globo h抗體之抗體-藥物共軛物及其用途
KR20250009592A (ko) 항-가변 muc1* 항체 및 그의 용도
JP2025506248A5 (cg-RX-API-DMAC7.html)
CN109414509B (zh) 使用双特异性抗体的抗体药物偶联物平台
JP2009529915A5 (cg-RX-API-DMAC7.html)
WO2018232164A1 (en) Antibody drug conjugates that bind lgr5
IL310175A (en) Methods for treating non-muscle invasive bladder cancer (NMIBC) with antibody-drug conjugates (ADC) that bind to 191P4D12 proteins
CN1946740B (zh) 抗人腱生蛋白单克隆抗体
CN119868576A (zh) 用于制备抗体与药物偶联物的中间体及其制备方法和应用
US7615221B2 (en) Compositions and methods for treating cancer